Axsome Therapeutics (AXSM) Financials: History & Chart

Axsome Therapeutics, Inc.(AXSM)

Biotechnology · New York City, NY

$174.91-2.17 (-1.22%)

Delayed quote: Oct 6, 2026, 1:05 PM EDT

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

New York City, NY

1,346 employees

www.axsome.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Herriot Tabuteau

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	776.57M	218.38M	191.20M	196.00M	170.99M	150.04M	121.46M	118.77M	104.76M
Cost of Goods Sold	52.53M	13.56M	14.72M	12.33M	11.91M	13.45M	9.79M	10.51M	8.44M
Gross Profit	724.04M	204.81M	176.48M	183.67M	159.08M	136.59M	111.67M	108.25M	96.33M
Gross Profit Margin	93.2%	93.8%	92.3%	93.7%	93.0%	91.0%	91.9%	91.1%	91.9%
Total Operating Expenses	912.58M	254.46M	239.84M	213.10M	205.19M	173.31M	168.66M	180.87M	158.95M
Research & Development	187.86M	46.23M	52.68M	48.79M	40.16M	49.54M	44.78M	55.01M	45.39M
Selling, General & Administrative	712.66M	208.14M	185.00M	169.30M	150.24M	130.28M	120.79M	113.27M	95.56M
Operating Income (EBIT)	-188.54M	-49.65M	-63.36M	-29.43M	-46.11M	-36.71M	-56.98M	-72.62M	-62.62M
Operating Margin	-24.3%	-22.7%	-33.1%	-15.0%	-27.0%	-24.5%	-46.9%	-61.1%	-59.8%
Income Before Tax (EBT)	-191.09M	-51.19M	-64.54M	-28.13M	-47.23M	-48.93M	-59.41M	-74.83M	-64.60M
Interest Income	2.04M	N/A	N/A	2.04M	N/A	N/A	N/A	N/A	N/A
Interest Expense	5.02M	1.54M	1.19M	1.17M	1.12M	1.83M	2.43M	2.21M	1.98M
Other Income/Expense	-2.54M	-1.54M	-1.19M	1.30M	-1.12M	-12.22M	-2.43M	-2.21M	-1.98M
Net Income	-191.64M	-51.31M	-64.54M	-28.56M	-47.23M	-47.97M	-59.41M	-74.91M	-64.60M
Income Tax Expense	558K	128K	0.00	430K	0.00	-960K	0.00	85K	0.00
Net Profit Margin	-24.7%	-23.5%	-33.8%	-14.6%	-27.6%	-32.0%	-48.9%	-63.1%	-61.7%
EBITDA	-181.21M	-48.59M	-61.08M	-27.16M	-44.38M	-34.47M	-54.85M	-70.54M	-60.56M
EBITDA Margin	-23.3%	-22.3%	-31.9%	-13.9%	-26.0%	-23.0%	-45.2%	-59.4%	-57.8%
Depreciation & Amortization	7.33M	1.05M	2.27M	2.27M	1.73M	2.25M	2.13M	2.07M	2.06M
EPS Basic	-3.75	-0.99	-1.26	-0.56	-0.94	-0.97	-1.22	-1.54	-1.34
EPS Diluted	-3.75	-0.99	-1.26	-0.56	-0.94	-0.97	-1.22	-1.54	-1.34
Weighted Average Basic Shares	51.50M	51.50M	51.20M	50.63M	50.02M	49.44M	48.87M	48.54M	48.14M
Weighted Average Diluted Shares	51.50M	51.50M	51.20M	50.63M	50.02M	49.44M	48.87M	48.54M	48.14M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	638.50M	385.69M	270.60M	50.04M	0.00	0.00	0.00	0.00
Cost of Goods Sold	47.48M	33.30M	26.07M	5.20M	0.00	0.00	37K	49K
Gross Profit	591.02M	352.39M	244.53M	44.84M	0.00	0.00	-37K	-49K
Gross Profit Margin	92.6%	91.4%	90.4%	89.6%	N/A	N/A	N/A	N/A
Total Operating Expenses	760.25M	632.95M	476.36M	224.64M	124.71M	99.14M	67.11M	32.85M
Research & Development	183.28M	187.08M	97.94M	57.95M	58.06M	70.24M	53.65M	23.50M
Selling, General & Administrative	570.60M	411.36M	323.12M	159.25M	66.65M	28.90M	13.60M	9.35M
Operating Income (EBIT)	-169.24M	-280.56M	-231.82M	-179.80M	-124.71M	-99.14M	-67.25M	-32.85M
Operating Margin	-26.5%	-72.7%	-85.7%	-359.3%	N/A	N/A	N/A	N/A
Income Before Tax (EBT)	-183.70M	-287.13M	-238.28M	-187.13M	-130.40M	-102.90M	-68.35M	-30.97M
Interest Income	9.37M	N/A	N/A	N/A	N/A	2.57M	1.24M	N/A
Interest Expense	6.56M	6.57M	6.45M	7.33M	5.70M	2.57M	1.24M	1.13M
Other Income/Expense	-14.47M	-6.57M	-6.45M	-7.33M	-5.70M	-3.76M	-1.10M	1.66M
Net Income	-183.17M	-287.22M	-239.24M	-187.13M	-130.40M	-102.90M	-68.35M	-30.97M
Income Tax Expense	-530K	85K	960K	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-28.7%	-74.5%	-88.4%	-374.0%	N/A	N/A	N/A	N/A
EBITDA	-160.17M	-272.60M	-224.99M	-175.40M	-124.63M	-99.06M	-67.21M	-32.80M
EBITDA Margin	-25.1%	-70.7%	-83.1%	-350.5%	N/A	N/A	N/A	N/A
Depreciation & Amortization	9.06M	7.96M	6.83M	4.40M	76K	78K	37K	49K
EPS Basic	-3.68	-5.99	-5.27	-4.60	-3.47	-2.83	-2.05	-1.15
EPS Diluted	-3.68	-5.99	-5.27	-4.60	-3.47	-2.83	-2.05	-1.15
Weighted Average Basic Shares	49.75M	47.91M	45.43M	40.66M	37.62M	37.21M	34.02M	26.88M
Weighted Average Diluted Shares	49.75M	47.91M	45.43M	40.66M	37.62M	37.21M	34.02M	26.88M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.